İçeriğe geç
akaturk Akademik ölçüm

Makale detayı · 2021 · article

Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation

ISSN1936-5233
YÖKSİS OpenAlex Açık erişim · gold
Yıl2021
Atıf22OpenAlex
Atıf19Semantic Scholar · 1 etkili
Yüzdelik%82,8
FWCI1,471,00 = dünya ortalaması
Scopus (SJR)Q2
WoS (JCR)Q2

Veri kaynağı ayrımı

  • YÖKSİSYÖKSİS makale kaydı
  • YÖKSİS dergi adıTranslational Oncology
  • Katalog eşleşmesi (ISSN)Translational Oncology
  • OpenAlexOpenAlex zenginleştirmesi (özet, atıf, konular)
  • Semantic Scholaratıf sayısı (OpenAlex ile birleştirilmez)

Özet

OpenAlex İngilizce

We analyzed potential biomarkers of response to ibrutinib plus nivolumab in biopsies from patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Richter's transformation (RT) from the LYM1002 phase I/IIa study, using programmed death ligand 1 (PD-L1) immunohistochemistry, whole exome sequencing (WES), and gene expression profiling (GEP). In DLBCL, PD-L1 elevation was more frequent in responders versus nonresponders (5/8 [62.5%] vs. 3/16 [18.8%]; p = 0.065; complete response 37.5% vs. 0%; p = 0.028). Overall response rates for patients with WES and GEP data, respectively, were: DLBCL (38.5% and 29.6%); FL (46.2% and 43.5%); RT (76.5% and 81.3%). In DLBCL, WES analyses demonstrated that mutations in RNF213 (40.0% vs. 6.2%; p = 0.055), KLHL14 (30.0% vs. 0%; p = 0.046), and LRP1B (30.0% vs. 6.2%; p = 0.264) were more frequent in responders. No responders had mutations in EBF1, ADAMTS20, AKAP9, TP53, MYD88, or TNFRSF14, while the frequency of these mutations in nonresponders ranged from 12.5% to 18.8%. In FL and RT, genes with different mutation frequencies in responders versus nonresponders were: BCL2 (75.0% vs. 28.6%; p = 0.047) and ROS1 (0% vs. 50.0%; p = 0.044), respectively. Per GEP, the most upregulated genes in responders were LEF1 and BTLA (overall), and CRTAM (germinal center B-cell-like DLBCL). Enriched pathways were related to immune activation in responders and resistance-associated proliferation/replication in nonresponders. This preliminary work may help to generate hypotheses regarding genetically defined subsets of DLBCL, FL, and RT patients most likely to benefit from ibrutinib plus nivolumab.

Konular

Atıflar

OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.

22atıfOpenAlex · cited_by_count (önbellek / veritabanı)

Yazarlar

14
  1. Brendan P.Hodkinson 1
  2. Michael Schaffer 2
  3. Joshua D. Brody 3
  4. Cecilia Carpio 4
  5. Wojciech Jurczak 5
  6. Dina Ben Yehuda 6
  7. Irit Avivi 7
  8. Ann Forslund 8
  9. MUHİT ÖZCAN ANKARA ÜNİVERSİTESİ 9
  10. John Alvarez 10
  11. Rob Ceulemans 11
  12. Nele Fourneau 12
  13. Anas Younes 13
  14. Sriram Balasubramanian 14